Market closed
Wave Life Sciences/$WVE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Wave Life Sciences
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Ticker
$WVE
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Singapore, Singapore
Employees
288
Website
WVE Metrics
BasicAdvanced
$939M
-
-$0.70
-1.04
-
Price and volume
Market cap
$939M
Beta
-1.04
52-week high
$15.84
52-week low
$4.25
Average daily volume
1.5M
Financial strength
Current ratio
2.888
Quick ratio
2.735
Long term debt to equity
8.172
Total debt to equity
11.686
Management effectiveness
Return on assets (TTM)
-22.00%
Return on equity (TTM)
-73.24%
Valuation
Price to revenue (TTM)
7.814
Price to book
4.47
Price to tangible book (TTM)
4.47
Price to free cash flow (TTM)
-5.569
Growth
Revenue change (TTM)
-4.42%
Earnings per share change (TTM)
29.42%
3-year revenue growth (CAGR)
38.28%
3-year earnings per share growth (CAGR)
-33.26%
What the Analysts think about WVE
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Wave Life Sciences stock.
WVE Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
WVE Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
WVE News
AllArticlesVideos
Wave Life Sciences: Potential For Accelerated Approval Pathway With WVE-N531
Seeking Alpha·4 weeks ago
Wave Life Sciences Stock Jumps On Positive Data From Muscle Disorder Drug, Plans FDA Submission Next Year
Benzinga·4 weeks ago
Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Wave Life Sciences stock?
Wave Life Sciences (WVE) has a market cap of $939M as of April 23, 2025.
What is the P/E ratio for Wave Life Sciences stock?
The price to earnings (P/E) ratio for Wave Life Sciences (WVE) stock is 0 as of April 23, 2025.
Does Wave Life Sciences stock pay dividends?
No, Wave Life Sciences (WVE) stock does not pay dividends to its shareholders as of April 23, 2025.
When is the next Wave Life Sciences dividend payment date?
Wave Life Sciences (WVE) stock does not pay dividends to its shareholders.
What is the beta indicator for Wave Life Sciences?
Wave Life Sciences (WVE) has a beta rating of -1.04. This means that it has an inverse relation to market volatility.